Takeda Pharmaceutical has a obtained new drug application approval for Copaxone Subcutaneous Injection
Singapore: Japan based Takeda Pharmaceutical has a obtained new drug application approval for Copaxone Subcutaneous Injection 20 mg Syringe (generic name: glatiramer acetate), for the treatment of multiple sclerosis, from the Japanese Ministry of Health, Labour and Welfare.
Developed by Teva Pharmaceutical, Copaxone is a subcutaneous injection administered once daily to prevent the relapse of multiple sclerosis.
In Japan, glatiramer acetate was developed as an unapproved new drug by Teva Pharmaceutical, a wholly owned subsidiary of Teva, at the request of the Japanese Ministry of Health, Labour and Welfare. In March, 2013, Takeda and Teva signed a licensing agreement in which Teva granted Takeda the right to commercialize glatiramer acetate in Japan.
